Kinnate Biopharma (KNTE) Social Stream



Kinnate Biopharma (KNTE): $10.10

0.85 (+9.19%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KNTE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 388

in industry

Kinnate Biopharma Inc (KNTE) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering Kinnate Biopharma Inc.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-10-28 6 $52 $32 $46.4 $10.97 322.97%
2021-11-11 6 $53 $32 $47 $10.97 328.44%
2022-02-02 6 $52 $35 $45.8 $10.97 317.5%
2022-03-29 6 $52 $33 $41 $10.97 273.75%

The Trend in the Analyst Price Target


KNTE's average price target has moved down $4.4 over the prior 152 days.

KNTE reports an average of 150.74% for its upside potential over the past 49 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-05-15 3 52 48 50.5 22.74 122.08%
2021-07-24 4 52 50 51.0 22.00 131.82%
2021-08-10 4 52 50 51.0 21.08 141.94%
2021-09-04 4 52 50 51.0 23.73 114.92%
2022-03-29 6 52 33 41.0 13.06 213.94%

KNTE Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 6 0 0 0 0 6

The Trend in the Broker Recommendations


Over the past 120 days, KNTE's average broker recommendation rating improved by 0.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for KNTE as an investment opportunity.

  • Kinnate Biopharma Inc's upside potential (average analyst target price relative to current price) is greater than 464.59% of all US stocks.
  • To contextualize these metrics, consider that out of stocks in the small market cap category, Kinnate Biopharma Inc's average analyst price target is greater than 420.6% of them.
  • In the context of stocks in the small market cap category, Kinnate Biopharma Inc's number of analysts covering the stock is higher than 389.5% of them.
  • In the context of Pharmaceutical Products stocks, Kinnate Biopharma Inc's variance in analysts' estimates is lower than -79.72% of them.

Stocks similar to Kinnate Biopharma Inc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are KNSA, KMPH, and KMDA.

Make investment decisions regarding KNTE using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6699 seconds.